USD10
ABVX Shares
About AbivaxAbivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.
USD10
ABVX Shares
About AbivaxAbivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.
Stats
TRADING WINDOW
Closed
OPENS AT
Mar 26 at 1:30 PM GMT+0
MARKET CAP
$8.67B
OPEN PRICE
$109.22
LOW (1Y)
$4.77
HIGH (1Y)
$148.83
LOW (24H)
$108.23
HIGH (24H)
$111.00
VOLUME (24H)
$848.40K
8.35%
Price history
Time | Price | Change |
|---|---|---|
Today | $109.22 | |
1 Day | $110.06 | |
1 Week | $123.49 | |
1 Month | $119.50 | |
1 Year | $6.82 |
Past performance is not a reliable indicator of future results.
Discover more
Legal
Information is provided for informational purposes only, and is not investment advice. This is not an invitation, inducement or recommendation to buy any particular asset, or to employ any particular investment strategy. Coinbase makes no representation as to the accuracy, suitability or validity of any information provided.All ticker names are trademarks of their respective holders. Any ticker reference does not imply affiliate with or endorsement by a third-party. Real-time prices are sourced from third parties, but not from all markets. Source: Nasdaq Last Sale. Morningstar data ©2026.
